Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay022 in HER2-Positive Advanced Breast Cancer
NCT02476539Phase 1Completed
- Sponsor
- Tianjin Hemay Biotech
- Start
- Oct 2015
- Primary completion
- Sep 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sacibertinib in breast cancer, sponsored by Tianjin Hemay Biotech. Primary endpoints: Number of participants with adverse events at 4 weeks, Observed maximum concentration of Hemay022 at Day 35 and 4 more. Started Oct 2015; status: completed.
02
Drugs
sacibertinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02476539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02476539.